Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 9/20 | 0.39 |
| ▸ | JAK3 | P52333 | 5/20 | 0.39 |
| ▸ | TYK2 | P29597 | 4/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.39 |
| ▸ | PAK4 | O96013 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | LTK | P29376 | 2/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14052892 | 0.82 | CCNE1 (0.44) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL14052891 | 0.82 | JAK2 (0.42) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL17451280 | 0.78 | CCNE1 (0.49) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL17451310 | 0.76 | JAK2 (0.43) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL2356289 | 0.75 | JAK2 (0.58) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL3306077 | 0.74 | CCNE1 (0.54) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL2358705 | 0.73 | CCNE1 (0.49) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL4410398 | 0.73 | CCNE1 (0.49) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL2357903 | 0.73 | JAK2 (0.41) | JAK1CDK2CCNE1JAK2JAK3 | |
| SCHEMBL17451307 | 0.73 | CCNE1 (0.58) | JAK1CDK2CCNE1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301464-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120301464-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | JAK1 1/4885CDK2 268/4885CCNE1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.